Clinical trial
TAC Versus TC for Adjuvant Breast Cancer
NCT00493870 · US Oncology Research, Industry · Completed
Key facts
| NCT number | NCT00493870 |
|---|---|
| Title | TAC Versus TC for Adjuvant Breast Cancer |
| Official title | Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients |
| Lead sponsor | US Oncology Research, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Doxorubicin, Cyclophosphamide |
| Enrollment | 1,961 |
| Start date | May 29, 2007 |
| Primary completion | May 31, 2015 |
| Completion | Mar 30, 2020 |
| First posted | Jun 28, 2007 |
| Last update posted | Mar 2, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: